Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma
Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · Annals of Oncology · 2014
Cited by 7 works. doi:10.1093/annonc/mdu438.39
Authors
- Caroline Robert
- Bogusława Karaszewska
- Jacob Schachter
- Piotr Lukasz Rutkowski
- Andrzej Adam Mackiewicz
- D. Stroiakovski
- M. Lichinitser
- Reinhard Dummer
- Florent Grange
- Laurent Mortier
- Vanna Chiarion‐Sileni
- Kamil Drucis
- Ivana Krajsová
- Axel Hauschild
- Peng Gang Sun
- S. D. Rubin
- Jeffrey J. Legos
- Wendy A. Crist
- Shonda Marie Little
- Dirk Schadendorf